Not All Bispecifics Are Equal: Mechanism-Based Approaches to Selection and Management in Oncology Practice

This activity was originally presented at the 2026 Oncology Pharmacists Connect Conference.

Program Description

Bispecific antibodies (BsAbs) are a class of immune therapies that are approved for various cancers, initially in hematological malignancies and now in solid tumors. Most currently available BsAbs engage T cells by targeting CD3 and a tumor antigen. Though primarily approved for previously treated patients, their use has moved to front-line settings. As BsAbs approvals expand, their varying mechanisms, toxicity profiles, and monitoring requirements add complexity to treatment decisions. Differences in target selection, structure, and immune engagement affect dosing, toxicity, and patient selection, presenting challenges for oncology pharmacists in clinical decision-making. In community oncology, incorporating BsAbs is crucial for patient access, though logistics and experience may hinder adoption. Additionally, the integration of BsAbs introduces new operational considerations such as complex dosing strategies, monitoring requirements, multidisciplinary coordination, and biomarker-driven patient identification. These factors can create workflow challenges across both academic and community oncology settings as clinical teams adapt to the expanding use of these therapies. Oncology pharmacists play a central role in developing treatment workflows, coordinating care delivery, and supporting patient access. This session reviews strategies for effective BsAb implementation, focusing on patient selection and toxicity management. Speakers will guide participants in translating emerging clinical evidence into implementation strategies that support safe and efficient delivery of BsAbs.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: June 30, 2026
Expiration date: June 30, 2027
Learner level: Intermediate, Advanced
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Differentiate bispecific antibody (BsAb) classes by mechanism and structure to inform dosing approaches, anticipate toxicity profiles, and guide patient selection
• Apply monitoring and supportive care strategies tailored to individual BsAbs for the management of treatment-related toxicities
• Optimize clinical workflows for the safe and effective implementation of individual BsAbs in oncology care settings